Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 5/20 | 0.41 |
| ▸ | CA1 | P00915 | 5/20 | 0.41 |
| ▸ | CA2 | P00918 | 5/20 | 0.41 |
| ▸ | CA9 | Q16790 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28290767 | 0.81 | L3MBTL1 (0.44) | TAAR1L3MBTL1ALDH1A1PKM | |
| SCHEMBL2878788 | 0.80 | CA1 (0.44) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL584619 | 0.80 | CA12 (0.41) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL29990322 | 0.80 | CA12 (0.41) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL2878422 | 0.80 | ALDH1A1 (0.50) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL1568982 | 0.79 | CPB2 (0.41) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL1568120 | 0.77 | STK17B (0.40) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL10264585 | 0.76 | LMNA (0.46) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL20399777 | 0.74 | BRD4 (0.41) | ALDH1A1BRD4GFERDRD2 | |
| SCHEMBL27968562 | 0.74 | L3MBTL1 (0.47) | TAAR1L3MBTL1ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768984-B1 | THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2010-10-20 | — | — | EP | disclosed |
| US-20100179123-A1 | THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-7601725-B2 | Thienopyrimidines useful as Aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20060035908-A1 | Thienopyrimidines useful as Aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179123-A1 | THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS | AURKA, AURKB, AURKC | TAAR1 3348/4885L3MBTL1 801/4885CA12 4800/4885 |
| US-20060035908-A1 | Thienopyrimidines useful as Aurora kinase inhibitors | AURKA, AURKB, AURKC | TAAR1 3518/4885L3MBTL1 646/4885CA12 4774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.